RestoriT
RestoriT has been established to develop therapeutic products to meet poorly met medical needs (e.g. satisfying the commercial opportunity that exists) because of the high percentage of men with erectile dysfunction who do not respond to phosphodiesterase inhibitor (PDEi,’Viagra’™). Target patient populations will include patients with erectile dysfunction (ED) arising as a consequence of prostatic surgery and post radical prostatectomy.
The RestoriT approach is based on a detailed understanding within the team of the biological foundation and clinical observation of profound erectile dysfunction. The first product QPD101 will be supported by patents based in clinical research. Subsequent products will be based on proprietary RestoriT formulation technology.
The RestoriT business model is predicated on rapid clinical proof of concept validation and subsequent out-licensing to commercial partners. In the case of the latter, potential partners have already been identified.